Rankings
▼
Calendar
RNAC FY 2024 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
RNAC
Cartesian Therapeutics, Inc.
$218M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$39M
+49.6% YoY
Gross Profit
$39M
100.0% margin
Operating Income
-$44M
-112.8% margin
Net Income
-$77M
-199.0% margin
EPS (Diluted)
$-3.29
Cash Flow
Operating Cash Flow
-$24M
Free Cash Flow
-$33M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$435M
Total Liabilities
$442M
Stockholders' Equity
-$7M
Cash & Equivalents
$213M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$39M
$26M
+49.6%
Gross Profit
$39M
$26M
+49.6%
Operating Income
-$44M
-$86M
+49.2%
Net Income
-$77M
-$220M
+64.8%
← Q4 2023
All Quarters
Q1 2024 →